Our lab's main focus is to obtain a better understanding of basic mechanisms of hemostasis and improving treatment for patients with hemophilia. Inhibitory antibodies to factor VIII, the protein that is missing in hemophilia, lead to serious bleeding problems in hemophiliacs. We are characterizing the regions of the factor VIII molecule to which these inhibitors bind.
Parker, E.T. Lollar, P. Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow. J. Biol. Chem. In press
Zakas, P.M., Healey, J.F., Smith, I.W., Lillicrap, D., Lollar, P. Sedimentation velocity analytical ultracentrifugation of oxidized recombinant full-length factor VIII. 2020 Front Immunol. 11:150-156.
Smith, I.W., d'Aquino, A.E., Coyle, C.W., Fedanov, A., Parker, E.T., Denning, G., Spencer, H.T., , Lollar, P., Doering, C.B., Spiegel, P.C., Jr. The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. 2019 J Thromb Haemost. 18:57-69.
Schureck, M. A., Meisner, J., Hoffer, E. D., Wang, D. X., Onuoha, N., Cho, S. E., Lollar, P., Dunham, C. M. Structural basis of transcriptional regulation by the HigA antitoxin. 2019 Molecular Microbiology 111: 1449-1462.
Doering, C.B., Denning, G., Shields, J.E., Fine, E.J., Parker, E.T., Srivastava, A., Lollar, P., Spencer, H.T. Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A. 2018 Hum Gene Therapy 29, 1183-1201
Batsuli, G., Ito, J., Mercer, R., Baldwin, W.H., Cox, C., Parker, E.T., Healey, J.F., Lollar, P., Meeks, S.L. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. 2018 J. Thromb. Haemost. 16, 1779-1788.
Healey, J.F., Parker, E.T., Lollar P. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation. 2018. J. Thromb. Haemost. 16, 303-315.